Ardaman Shergill, MD, University of Chicago, Chicago, IL, discusses the role of circulating tumor DNA (ctDNA) and liquid biopsies in patients with colorectal cancer (CRC). In the case of RAS wild-type, resistance to anti-EFGR therapies can occur, and liquid biopsies can detect tumor cells that confer resistance genes. Patients can subsequently be rechallenged with anti-EGFR regimens, and have their response assessed. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Gastrointestinal Cancers (GI) Symposium in San Francisco, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
View our new feature exploring genomic biomarkers in metastatic colorectal cancer here: https://bit.ly/3DcSevZ